Skip to main content
Top
Published in: Virology Journal 1/2007

Open Access 01-12-2007 | Short report

Relationship between the loss of neutralizing antibody binding and fusion activity of the F protein of human respiratory syncytial virus

Authors: Changbao Liu, Nicole D Day, Patrick J Branigan, Lester L Gutshall, Robert T Sarisky, Alfred M Del Vecchio

Published in: Virology Journal | Issue 1/2007

Login to get access

Abstract

To elucidate the relationship between resistance to HRSV neutralizing antibodies directed against the F protein and the fusion activity of the F protein, a recombinant approach was used to generate a panel of mutations in the major antigenic sites of the F protein. These mutant proteins were assayed for neutralizing mAb binding (ch101F, palivizumab, and MAb19), level of expression, post-translational processing, cell surface expression, and fusion activity. Functional analysis of the fusion activity of the panel of mutations revealed that the fusion activity of the F protein is tolerant to multiple changes in the site II and IV/V/VI region in contrast with the somewhat limited spectrum of changes in the F protein identified from the isolation of HRSV neutralizing antibody virus escape mutants. This finding suggests that aspects other than fusion activity may limit the spectrum of changes tolerated within the F protein that are selected for by neutralizing antibodies.
Literature
1.
go back to reference Stensballe LG, Devasundaram JK, Simoes EA: Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus. Pediatr Infect Dis J. 2003, 22: S21-32. 10.1097/00006454-200302001-00004.PubMed Stensballe LG, Devasundaram JK, Simoes EA: Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus. Pediatr Infect Dis J. 2003, 22: S21-32. 10.1097/00006454-200302001-00004.PubMed
2.
go back to reference Anderson LJ, Bingham P, Hierholzer JC: Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies. J Virol. 1988, 62: 4232-4238.PubMedPubMedCentral Anderson LJ, Bingham P, Hierholzer JC: Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies. J Virol. 1988, 62: 4232-4238.PubMedPubMedCentral
3.
go back to reference Beeler JA, van Wyke Coelingh K: Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol. 1989, 63: 2941-2950.PubMedPubMedCentral Beeler JA, van Wyke Coelingh K: Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol. 1989, 63: 2941-2950.PubMedPubMedCentral
4.
go back to reference Garcia-Barreno B, Palomo C, Penas C, Delgado T, Perez-Brena P, Melero JA: Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins. J Virol. 1989, 63: 925-932.PubMedPubMedCentral Garcia-Barreno B, Palomo C, Penas C, Delgado T, Perez-Brena P, Melero JA: Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins. J Virol. 1989, 63: 925-932.PubMedPubMedCentral
5.
go back to reference Trudel M, Nadon F, Seguin C, Payment P, Talbot PJ: Respiratory syncytial virus fusion glycoprotein: further characterization of a major epitope involved in virus neutralization. Can J Microbiol. 1987, 33: 933-938.PubMedCrossRef Trudel M, Nadon F, Seguin C, Payment P, Talbot PJ: Respiratory syncytial virus fusion glycoprotein: further characterization of a major epitope involved in virus neutralization. Can J Microbiol. 1987, 33: 933-938.PubMedCrossRef
6.
go back to reference Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC, Young JF: Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997, 176: 1215-1224.PubMedCrossRef Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC, Young JF: Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997, 176: 1215-1224.PubMedCrossRef
7.
go back to reference Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, Connor EM, Sondheimer HM: Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003, 143: 532-540. 10.1067/S0022-3476(03)00454-2.PubMedCrossRef Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, Connor EM, Sondheimer HM: Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003, 143: 532-540. 10.1067/S0022-3476(03)00454-2.PubMedCrossRef
8.
go back to reference DeVincenzo JP, Hall CB, Kimberlin DW, Sanchez PJ, Rodriguez WJ, Jantausch BA, Corey L, Kahn JS, Englund JA, Suzich JA, Palmer-Hill FJ, Branco L, Johnson S, Patel NK, Piazza FM: Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. J Infect Dis. 2004, 190: 975-978. 10.1086/423213.PubMedCrossRef DeVincenzo JP, Hall CB, Kimberlin DW, Sanchez PJ, Rodriguez WJ, Jantausch BA, Corey L, Kahn JS, Englund JA, Suzich JA, Palmer-Hill FJ, Branco L, Johnson S, Patel NK, Piazza FM: Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. J Infect Dis. 2004, 190: 975-978. 10.1086/423213.PubMedCrossRef
9.
go back to reference Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA: Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol. 2007, 368: 652-665. 10.1016/j.jmb.2007.02.024.PubMedCrossRef Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA: Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol. 2007, 368: 652-665. 10.1016/j.jmb.2007.02.024.PubMedCrossRef
10.
go back to reference Young JF, Koenig S, Johnson LS: Anti-RSV Antibodies. 2004, USA, MedImmune, Inc. Young JF, Koenig S, Johnson LS: Anti-RSV Antibodies. 2004, USA, MedImmune, Inc.
11.
go back to reference Zhao X, Liu E, Chen FP, Sullender WM: In vitro and in vivo fitness of respiratory syncytial virus monoclonal antibody escape mutants. J Virol. 2006, 80: 11651-11657. 10.1128/JVI.01387-06.PubMedPubMedCentralCrossRef Zhao X, Liu E, Chen FP, Sullender WM: In vitro and in vivo fitness of respiratory syncytial virus monoclonal antibody escape mutants. J Virol. 2006, 80: 11651-11657. 10.1128/JVI.01387-06.PubMedPubMedCentralCrossRef
12.
go back to reference Zhao X, Sullender WM: In vivo selection of respiratory syncytial viruses resistant to palivizumab. J Virol. 2005, 79: 3962-3968. 10.1128/JVI.79.7.3962-3968.2005.PubMedPubMedCentralCrossRef Zhao X, Sullender WM: In vivo selection of respiratory syncytial viruses resistant to palivizumab. J Virol. 2005, 79: 3962-3968. 10.1128/JVI.79.7.3962-3968.2005.PubMedPubMedCentralCrossRef
13.
go back to reference Zhao X, Chen FP, Megaw AG, Sullender WM: Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants. J Infect Dis. 2004, 190: 1941-1946. 10.1086/425515.PubMedCrossRef Zhao X, Chen FP, Megaw AG, Sullender WM: Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants. J Infect Dis. 2004, 190: 1941-1946. 10.1086/425515.PubMedCrossRef
14.
go back to reference Zhao X, Chen FP, Sullender WM: Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats. Virology. 2004, 318: 608-612. 10.1016/j.virol.2003.10.018.PubMedCrossRef Zhao X, Chen FP, Sullender WM: Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats. Virology. 2004, 318: 608-612. 10.1016/j.virol.2003.10.018.PubMedCrossRef
15.
go back to reference Taylor G, Stott EJ, Furze J, Ford J, Sopp P: Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies. J Gen Virol. 1992, 73 ( Pt 9): 2217-2223.CrossRef Taylor G, Stott EJ, Furze J, Ford J, Sopp P: Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies. J Gen Virol. 1992, 73 ( Pt 9): 2217-2223.CrossRef
16.
go back to reference Everitt DE, Davis CB, Thompson K, DiCicco R, Ilson B, Demuth SG, Herzyk DJ, Jorkasky DK: The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers. J Infect Dis. 1996, 174: 463-469.PubMedCrossRef Everitt DE, Davis CB, Thompson K, DiCicco R, Ilson B, Demuth SG, Herzyk DJ, Jorkasky DK: The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers. J Infect Dis. 1996, 174: 463-469.PubMedCrossRef
17.
go back to reference Wyde PR, Moore DK, Hepburn T, Silverman CL, Porter TG, Gross M, Taylor G, Demuth SG, Dillon SB: Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats. Pediatr Res. 1995, 38: 543-550. 10.1203/00006450-199510000-00012.PubMedCrossRef Wyde PR, Moore DK, Hepburn T, Silverman CL, Porter TG, Gross M, Taylor G, Demuth SG, Dillon SB: Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats. Pediatr Res. 1995, 38: 543-550. 10.1203/00006450-199510000-00012.PubMedCrossRef
18.
go back to reference Arbiza J, Taylor G, Lopez JA, Furze J, Wyld S, Whyte P, Stott EJ, Wertz G, Sullender W, Trudel M, et al: Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. J Gen Virol. 1992, 73 ( Pt 9): 2225-2234.CrossRef Arbiza J, Taylor G, Lopez JA, Furze J, Wyld S, Whyte P, Stott EJ, Wertz G, Sullender W, Trudel M, et al: Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. J Gen Virol. 1992, 73 ( Pt 9): 2225-2234.CrossRef
19.
go back to reference Lopez JA, Bustos R, Orvell C, Berois M, Arbiza J, Garcia-Barreno B, Melero JA: Antigenic structure of human respiratory syncytial virus fusion glycoprotein. J Virol. 1998, 72: 6922-6928.PubMedPubMedCentral Lopez JA, Bustos R, Orvell C, Berois M, Arbiza J, Garcia-Barreno B, Melero JA: Antigenic structure of human respiratory syncytial virus fusion glycoprotein. J Virol. 1998, 72: 6922-6928.PubMedPubMedCentral
20.
go back to reference Wu SJ, Schmidt A, Beil EJ, Day ND, Branigan PJ, Liu C, Gutshall LL, Palomod C, Furze J, Taylor G, Melero JA, Tsui P, Del Vecchio AM, Kruszynski M: Characterization of the epitope for anti human respiratory syncytial virus F protein monoclonal antibody 101F using synthetic peptides and genetic approaches. J Gen Virol. submitted: Wu SJ, Schmidt A, Beil EJ, Day ND, Branigan PJ, Liu C, Gutshall LL, Palomod C, Furze J, Taylor G, Melero JA, Tsui P, Del Vecchio AM, Kruszynski M: Characterization of the epitope for anti human respiratory syncytial virus F protein monoclonal antibody 101F using synthetic peptides and genetic approaches. J Gen Virol. submitted:
21.
go back to reference Day ND, Branigan PJ, Liu C, Gutshall LL, Luo J, Melero JA, Sarisky RT, Del Vecchio AM: Contribution of cysteine residues in the extracellular domain of the F protein of human respiratory syncytial virus to its function. Virol J. 2006, 3: 34-10.1186/1743-422X-3-34.PubMedPubMedCentralCrossRef Day ND, Branigan PJ, Liu C, Gutshall LL, Luo J, Melero JA, Sarisky RT, Del Vecchio AM: Contribution of cysteine residues in the extracellular domain of the F protein of human respiratory syncytial virus to its function. Virol J. 2006, 3: 34-10.1186/1743-422X-3-34.PubMedPubMedCentralCrossRef
22.
go back to reference Cardenas S, Auais A, Piedimonte G: Palivizumab in the prophylaxis of respiratory syncytial virus infection. Expert Rev Anti Infect Ther. 2005, 3: 719-726. 10.1586/14787210.3.5.719.PubMedCrossRef Cardenas S, Auais A, Piedimonte G: Palivizumab in the prophylaxis of respiratory syncytial virus infection. Expert Rev Anti Infect Ther. 2005, 3: 719-726. 10.1586/14787210.3.5.719.PubMedCrossRef
23.
go back to reference Johnson S, Griego SD, Pfarr DS, Doyle ML, Woods R, Carlin D, Prince GA, Koenig S, Young JF, Dillon SB: A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9. J Infect Dis. 1999, 180: 35-40. 10.1086/314846.PubMedCrossRef Johnson S, Griego SD, Pfarr DS, Doyle ML, Woods R, Carlin D, Prince GA, Koenig S, Young JF, Dillon SB: A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9. J Infect Dis. 1999, 180: 35-40. 10.1086/314846.PubMedCrossRef
24.
go back to reference Crowe JE, Firestone CY, Crim R, Beeler JA, Coelingh KL, Barbas CF, Burton DR, Chanock RM, Murphy BR: Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein. Virology. 1998, 252: 373-375. 10.1006/viro.1998.9462.PubMedCrossRef Crowe JE, Firestone CY, Crim R, Beeler JA, Coelingh KL, Barbas CF, Burton DR, Chanock RM, Murphy BR: Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein. Virology. 1998, 252: 373-375. 10.1006/viro.1998.9462.PubMedCrossRef
25.
go back to reference Karron RA, Wright PF, Crowe JE, Clements-Mann ML, Thompson J, Makhene M, Casey R, Murphy BR: Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis. 1997, 176: 1428-1436.PubMedCrossRef Karron RA, Wright PF, Crowe JE, Clements-Mann ML, Thompson J, Makhene M, Casey R, Murphy BR: Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis. 1997, 176: 1428-1436.PubMedCrossRef
26.
go back to reference Teng MN, Collins PL: Identification of the respiratory syncytial virus proteins required for formation and passage of helper-dependent infectious particles. J Virol. 1998, 72: 5707-5716.PubMedPubMedCentral Teng MN, Collins PL: Identification of the respiratory syncytial virus proteins required for formation and passage of helper-dependent infectious particles. J Virol. 1998, 72: 5707-5716.PubMedPubMedCentral
27.
go back to reference Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology. 2001, 289: 283-296. 10.1006/viro.2001.1138.PubMedCrossRef Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology. 2001, 289: 283-296. 10.1006/viro.2001.1138.PubMedCrossRef
28.
go back to reference Techaarpornkul S, Barretto N, Peeples ME: Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene. J Virol. 2001, 75: 6825-6834. 10.1128/JVI.75.15.6825-6834.2001.PubMedPubMedCentralCrossRef Techaarpornkul S, Barretto N, Peeples ME: Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene. J Virol. 2001, 75: 6825-6834. 10.1128/JVI.75.15.6825-6834.2001.PubMedPubMedCentralCrossRef
29.
go back to reference Techaarpornkul S, Collins PL, Peeples ME: Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus. Virology. 2002, 294: 296-304. 10.1006/viro.2001.1340.PubMedCrossRef Techaarpornkul S, Collins PL, Peeples ME: Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus. Virology. 2002, 294: 296-304. 10.1006/viro.2001.1340.PubMedCrossRef
30.
go back to reference Branigan PJ, Liu C, Day ND, Gutshall LL, Sarisky RT, Del Vecchio AM: Use of a novel cell-based fusion reporter assay to explore the host range of human respiratory syncytial virus F protein. Virol J. 2005, 2: 54-10.1186/1743-422X-2-54.PubMedPubMedCentralCrossRef Branigan PJ, Liu C, Day ND, Gutshall LL, Sarisky RT, Del Vecchio AM: Use of a novel cell-based fusion reporter assay to explore the host range of human respiratory syncytial virus F protein. Virol J. 2005, 2: 54-10.1186/1743-422X-2-54.PubMedPubMedCentralCrossRef
Metadata
Title
Relationship between the loss of neutralizing antibody binding and fusion activity of the F protein of human respiratory syncytial virus
Authors
Changbao Liu
Nicole D Day
Patrick J Branigan
Lester L Gutshall
Robert T Sarisky
Alfred M Del Vecchio
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2007
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-4-71

Other articles of this Issue 1/2007

Virology Journal 1/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.